Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $770.0 million
Deal Type : Licensing Agreement
Details : The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $770.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AUT00201
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : AUT00201
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUT00206
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.1 million
Deal Type : Termination
Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme
Details : Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $29.5 million
August 26, 2020
Lead Product(s) : AUT00206
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $50.1 million
Deal Type : Termination
Lead Product(s) : AUT00201
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Blood Levels and Effects of AUT00201
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2019
Lead Product(s) : AUT00201
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUT00206
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : King's College London
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2017
Lead Product(s) : AUT00206
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : King's College London
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUT00206
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : University of Manchester
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2016
Lead Product(s) : AUT00206
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : University of Manchester
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUT00063
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 14, 2016
Lead Product(s) : AUT00063
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUT00206
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Blood Levels and Effects of AUT00206
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2015
Lead Product(s) : AUT00206
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUT00063
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 26, 2015
Lead Product(s) : AUT00063
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUT00063
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : University of Nottingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2014
Lead Product(s) : AUT00063
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : University of Nottingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
